BH3120: A novel bispecific antibody targeting 4-1BB and PD-L1 with well balanced efficacy and safety profiles.

被引：0

作者：

Xu, Jiangcheng ^{[1
]}

Liu, Yang ^{[1
]}

Wang, Jing ^{[1
]}

Fan, Fei ^{[1
]}

Gu, Haitao ^{[1
]}

Zhang, Lanxin ^{[1
]}

Wang, Jun ^{[1
]}

Song, Ding ^{[1
]}

Guo, Ailong ^{[1
]}

Zhang, Hongjuan ^{[1
]}

Su, Kaixuan ^{[1
]}

Su, Jiaojiao ^{[1
]}

Li, Lijuan ^{[1
]}

Cai, Jingmei ^{[1
]}

Zhang, Aihong ^{[1
]}

Liu, Jiawang ^{[1
]}

Lee, Kyoungwoo ^{[1
]}

机构：

[1] Beijing Hanmi Res Ctr, Beijing, Peoples R China

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5605

引用

页数：1

共 50 条

[1] BH3120, a bispecific antibody targeting 4-1BB and PD-L1 simultaneously, stimulates T cells in tumor tissue preferred manner
Wang, Jing
Wang, Jun
Liu, Yang
Pang, Yan
Zhang, Aihong
Feng, Jie
Sun, Aibo
Ma, Xiao
Cai, Jingmei
Xu, Jiangcheng
Liu, Jiawang
Lee, Kyoungwoo
CANCER RESEARCH, 2023, 83 (07)
[2] BH3120, PD-L1 X 4-1BB bispecific antibody, plus PD-1 antagonist results in synergistic anti-tumor efficacy with excellent safety profile
Wang, Jun
Wang, Jing
Liu, Yang
Xu, Jiangcheng
Liu, Jiawang
Lee, Kyoungwoo
CANCER RESEARCH, 2024, 84 (06)
[3] Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors
Falchook, Gerald Steven
LoRusso, Patricia
Goldman, Jonathan W.
El-Khoueiry, Anthony B.
Tolcher, Anthony W.
Xing, Yan
Henry, Jason Timothy
Keam, Bhumsuk
Kim, Dong-Wan
Kim, Tae-Yong
Kim, Hye Ryun
Hong, Min Hee
Kim, Min Hwan
Lee, Dae Ho
Lee, SangMi
Jeon, JuYeun
Hayslip, John W.
Xu, Cong
Garon, Edward B.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[4] Phase I safety and preliminary efficacy of PM1003, a bispecific antibody targeting PD-L1 and 4-1BB, in patients with advanced solid tumors
Xue, Junli
Sun, Yuping
Li, DaPeng
Guo, Ye
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] GEN1046 (Bispecific Antibody Targeting PD-L1 and 4-1BB): Preclinical Characteristics and Phase 1 Results in Solid Tumors
Kunkel, Maria
Muik, Alexander
Altintas, Isil
Gieseke, Friederike
Schodel, Kristina
Diken, Mustafa
Sette, Angelica
Stanganello, Eliana
Vascotto, Fulvia
Breij, Esther
Sasser, Kate
Tureci, Ozlem
Forssmann, Ulf
Ahmadi, Tahamtan
Sahin, Ugur
CANCER SCIENCE, 2023, 114 : 1566 - 1566
[6] The bispecific antibody KA-3004, targeting PD-L1 and 4-1BB, is designed to enhance anti- tumor activity
Liang, Jiabei
Guo, Zhengcheng
Peng, Hao
Hao, Feng
Liu, Tongtong
Ning, Jinying
Wu, Guojin
CANCER RESEARCH, 2024, 84 (06)
[7] Development of a novel MSLN x 4-1BB bispecific antibody
Li, Liangwei
Zhang, Dayan
Shen, Guodong
Liu, Wenting
Zeng, Xiaoli
Wu, Lingling
Zhao, Qun
Zhou, Weiming
Huang, Yang
Cheng, Liansheng
CANCER RESEARCH, 2023, 83 (07)
[8] ATG-101 Is a Tetravalent PD-L1x4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation
Hui, Yuwen
Wang, Huajing
Li, Tengteng
Ren, Yijing
Zhang, Yun-kai
Chen, Peng
Sun, Ao
Bian, Gang
Li, Bohua
Flowers, David
Presler, Marc
Subramanian, Kalyanasundaram
Xue, Jia
Wang, Jingjing
Lynch, Kevin
Mei, Jay
He, Xiaowen
Shan, Bo
Hou, Bing
CANCER RESEARCH, 2024, 84 (10) : 1680 - 1698
[9] An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity
Cheng, Lian-sheng
Zhu, Min
Gao, Yan
Liu, Wen-ting
Yin, Wu
Zhou, Pengfei
Zhu, Zhongliang
Niu, Liwen
Zeng, Xiaoli
Zhang, Dayan
Fang, Qing
Wang, Fengrong
Zhao, Qun
Zhang, Yan
Shen, Guodong
CELLULAR & MOLECULAR BIOLOGY LETTERS, 2023, 28 (01)
[10] An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity
Lian-sheng Cheng
Min Zhu
Yan Gao
Wen-ting Liu
Wu Yin
Pengfei Zhou
Zhongliang Zhu
Liwen Niu
Xiaoli Zeng
Dayan Zhang
Qing Fang
Fengrong Wang
Qun Zhao
Yan Zhang
Guodong Shen
Cellular & Molecular Biology Letters, 28

← 1 2 3 4 5 →